Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01645 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Parnian Mehinrad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada. Hauptthemen laut MEDLINE: Liposomes, Colorectal Neoplasms, Endonucleases, DNA-Binding Proteins. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research, Alberta Cancer Foundation.
Abstract (Originalsprache)
Inhibition of ERCC1/XPF, a heterodimeric enzyme complex with endonuclease activity that participates in the repair of DNA inter- and intrastrand cross-links, is expected to make cells sensitive to DNA damage by platinum-based chemotherapeutics. Here we report on repurposing a clinically used antimalaria drug, pyronaridine (PYD), as a novel inhibitor of ERCC1/XPF for the sensitization of colorectal cancer cells (CRC) to platinum drugs. We have developed a liposomal formulation of PYD to make the chemosensitizing activity of this ERCC1/XPF inhibitor more specific to the tumor site. Liposomal PYD was optimized by changing the lipid composition and the pH gradient system within the liposomes. Prepared formulations were characterized for their average diameter, PYD encapsulation, and in vitro drug release. The intracellular XPF-PYD interaction and subsequent XPF protein thermal stabilization in intact HCT116 cells were confirmed by the cellular thermal shift assay (CETSA). The cytotoxic activity of free and selected PYD liposomal formulation alone or in combination with carboplatin and oxaliplatin was assessed against HCT116 and SW620 cells using MTT and colony-forming assays. The possibility of a synergistic effect between PYD or liposomal PYD and Pt-based chemotherapeutics in HCT116 was tested through analyzing the MTT assays using the Combenefit software. The results showed an average diameter of 82.32 ± 0.33 nm with a polydispersity index of 0.181 ± 0.008 along with a 99% PYD encapsulation efficiency for the optimized liposomal formulations prepared using a combination of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG), and cholesterol with an inside pH of 3.5. In media consisting of PBS and bovine serum albumin, ∼50% of the loaded PYD was released within 72 h. The validation of target interaction performed via CETSA in vitro demonstrated the significant thermal stabilization of XPF after treatment with either free or liposomal PYD at the temperature range of 47-50 °C. Combenefit analysis showed synergy in HCT116 cells between PYD and carboplatin, which was further increased when carboplatin was combined with liposomal PYD. Oxaliplatin and PYD combination displayed less synergy in HCT116 cells, while combining oxaliplatin and liposomal PYD only showed an additive effect in this cell line. In SW620 cells, an elevated level of PYD was needed (0.6 μM) for the sensitization of cells to the effect of carboplatin or oxaliplatin. The colony-forming assay in HCT116 cells evidenced a decrease of colony formation when PYD (0.15 μM) was combined with carboplatin or oxaliplatin. In SW620, a higher PYD concentration (0.6 μM) was required to significantly lower colony formation when paired with carboplatin, suggesting lower sensitivity compared to HCT116 cells. The same trend was seen with the oxaliplatin combination. The results indicate a potential for PYD and its liposomal formulation in the chemosensitization of CRC to platinum chemotherapeutics in a cell-dependent manner.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2R3, Canada.
- Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
- Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan 2021, Iran.
- Department of Chemistry, Faculty of Science, University of Alberta, Edmonton, AB T6G 2R3, Canada.
- Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
- Department of Experimental Oncology, Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada.
ORCID-Profile: Michael Weinfeld, Afsaneh Lavasanifar
Förderung
- Canadian Institutes of Health Research
- Alberta Cancer Foundation
Zitieren
APA
Mehinrad, P., Abdelfattah, A., Shafaati, T., Emami, J., Donnelly, J., West, F. G., Weinfeld, M., & Lavasanifar, A. (2026). Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01645
Vancouver
Mehinrad P, Abdelfattah A, Shafaati T, Emami J, Donnelly J, West FG, et al. Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01645
BibTeX
@article{Mehinrad2026,
author = {Mehinrad, Parnian and Abdelfattah, Ahmed and Shafaati, Tanin and Emami, Jaber and Donnelly, James and West, Frederick G and Weinfeld, Michael and Lavasanifar, Afsaneh},
title = {Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01645}
}
EUVIMED